Clinical Trial

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-07; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT06770452
Lead Sponsor Zhejiang University
Conditions Metastatic Pancreatic Carcinoma
Enrollment 133 participants
Start Date 2025-03-25
Primary Completion 2027-02-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-03